Table 2.
Characteristics, treatment parameters, and acute hematological adverse events of AYA patients who received photon CSI
| Case no. | Age (years) | Sex | Histology | Chemotherapy regimen | Total dose (Gy) | Acute hematological AEs within 4 weeks after CSI | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre CSI | Concurrent CSI | Post CSI | CSI | Intracranial boost | Spinal boost | WBC | Hb | Platelet | ||||
| 1 | 25 | M | GCT | (IFOS-CDDP-VP-16) × 3 | none | none | 25.2 | 25.2 | none | Gr. 2 | Gr. 2 | Gr. 1 |
| 2 | 26 | F | PNET | (IFOS-CDDP-VP-16) × 1 | none | (IFOS-CDDP-VP-16) × 4 | 25.2 | 28.8 | none | Gr. 2 | Gr. 2 | Gr. 3 |
| 3 | 28 | M | GCT | (CBDCA+VP-16) × 2 | none | none | 25.2 | 25.2 | none | Gr. 3 | Gr. 2 | Gr. 1 |
| (IFOS-CDDP-VP-16) × 2 | ||||||||||||
| 4 | 26 | F | PNET | (CBDCA+VP-16) × 1 | none | none | 36.0 | none | none | Gr. 2 | Gr. 3 | Gr. 2 |
| 5 | 21 | M | GCT | (CBDCA+VP-16) × 3 | none | none | 23.4 | 27.0 | none | Gr. 3 | Gr. 1 | Gr. 1 |
| 6 | 18 | F | MB | none | (IFOS-CDDP-VP-16) × 1 | (IFOS-CDDP-VP-16) × 4 | 23.4 | 32.4 | none | Gr. 3 | Gr. 2 | Gr. 0 |
| 7 | 28 | F | PNET | none | none | (CDDP+VP-16) × 2 | 25.2 | 28.8 | none | Gr. 2 | Gr. 1 | Gr. 0 |
| TMZ × 2 | ||||||||||||
| 8 | 24 | M | GCT | (IFOS-CDDP-VP-16) × 4 | none | none | 25.2 | none | none | Gr. 3 | Gr. 1 | Gr. 0 |
AYA = adolescent and young adult, CSI = craniospinal irradiation, ipCSI = intensity-modulated proton craniospinal irradiation, AEs = adverse events, M = male, F = female, WBC = white blood cell, Hb = hemoglobin, GCT = germ cell tumor, PNET = primitive neuroectodermal tumor, MB = medulloblastoma, IFOS = ifosfamide, CDDP = cisplatin, VP-16 = etoposide, CBDCA = carboplatin, TMZ = temozolomide.